(Q34261229)

8 July 2018

title

Prostate-cancer mortality at 11 years of follow-up (English)

1 reference

8 July 2018

1 reference

9

1 reference

8 July 2018

Kimmo Taari

25

1 reference

8 July 2018

Anssi Auvinen

29

1 reference

8 July 2018

Arnauld Villers

Arnauld Villers

Theodorus H Van der Kwast

18

0 references

Theodorus van der Kwast

20

0 references

Xavier Rebillard

19

Xavier Rebillard

1 reference

8 July 2018

Stefano Ciatto

5

Stefano Ciatto

1 reference

8 July 2018

Teuvo L Tammela

4

Teuvo L J Tammela

1 reference

8 July 2018

Chris H Bangma

15

Chris H Bangma

1 reference

8 July 2018

Vera Nelen

6

Vera Nelen

1 reference

8 July 2018

Jonas Hugosson

2

Jonas Hugosson

1 reference

8 July 2018

Monique Roobol

3

Monique J Roobol

1 reference

8 July 2018

Maciej Kwiatkowski

7

Maciej Kwiatkowski

1 reference

8 July 2018

Franz Recker

12

Franz Recker

1 reference

8 July 2018

Marco Zappa

10

Marco Zappa

1 reference

8 July 2018

author name string

Fritz H Schröder

1

1 reference

8 July 2018

Marcos Lujan

8

1 reference

8 July 2018

Louis J Denis

11

1 reference

8 July 2018

Alvaro Páez

13

1 reference

8 July 2018

Liisa Määttänen

14

1 reference

8 July 2018

Gunnar Aus

16

1 reference

8 July 2018

Sigrid Carlsson

17

1 reference

8 July 2018

Paula M Kujala

21

1 reference

8 July 2018

Bert G Blijenberg

22

1 reference

8 July 2018

Ulf-Hakan Stenman

23

1 reference

8 July 2018

Andreas Huber

24

1 reference

8 July 2018

Matti Hakama

26

1 reference

8 July 2018

Sue M Moss

27

1 reference

8 July 2018

Harry J de Koning

28

1 reference

8 July 2018

ERSPC Investigators

30

1 reference

8 July 2018

language of work or name

English

0 references

publication date

1 March 2012

1 reference

8 July 2018

The New England Journal of Medicine

published in

1 reference

8 July 2018

volume

366

1 reference

8 July 2018

issue

11

1 reference

8 July 2018

page(s)

981-990

1 reference

8 July 2018

Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6027585

Complications after prostate biopsy: data from SEER-Medicare

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6027585

What is the true number needed to screen and treat to save a life with prostate-specific antigen testing?

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6027585

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6027585

Screening and prostate-cancer mortality in a randomized European study

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6027585

Number needed to screen: development of a statistic for disease screening.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6027585

Making the most out of six systematic sextant biopsies

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6027585

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6027585

A stochastic model for survival of early prostate cancer with adjustments for leadtime, length bias, and over-detection.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6027585

Radical prostatectomy versus watchful waiting in early prostate cancer

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6027585

Change of tumour characteristics and treatment over time in both arms of the European Randomized study of Screening for Prostate Cancer

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6027585

The effect of study arm on prostate cancer treatment in the large screening trial ERSPC.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6027585

Natural History of Early, Localized Prostate Cancer

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6027585

Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6027585

Determining the cause of death in randomized screening trial(s) for prostate cancer.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6027585

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6027585

Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6027585

Interim analysis: the alpha spending function approach.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6027585

Monitoring the ERSPC trial

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6027585

Prostate cancer mortality reduction by screening: Power and time frame with complete enrollment in the European randomised screening for prostate cancer (ERSPC) trial

9 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22417251

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Adjusting for non-compliance and contamination in randomized clinical trials

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22417251

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1056/NEJMOA1113135

1 reference

8 July 2018

PMCID

6027585

1 reference

8 July 2018

PubMed ID

22417251

1 reference

8 July 2018